CL2012001133A1 - Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo. - Google Patents

Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo.

Info

Publication number: CL2012001133A1
Authority: CL; Chile
Prior art keywords: methyl; ylethynyl; ponatinib; pyridazin; methylpiperazin
Prior art date: 2009-10-30

Application number

CL2012001133A

Other languages

English (en)

Inventor

Weisheng Huang

Victor M Rivera

Timothy P Shakespeare William C Clackson

Rachel M Squillace

M Gozgit Joseph

Original Assignee

Ariad Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-30

Filing date

2012-04-30

Publication date

2013-08-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001133(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-04-30 Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc

2013-08-02 Publication of CL2012001133A1 publication Critical patent/CL2012001133A1/es

Links

206010028980 Neoplasm Diseases 0.000 title 2
PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 title 2
239000002137 L01XE24 - Ponatinib Substances 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
208000035269 cancer or benign tumor Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000003463 hyperproliferative effect Effects 0.000 title 1
239000008203 oral pharmaceutical composition Substances 0.000 title 1
239000000546 pharmaceutical excipient Substances 0.000 title 1
229960001131 ponatinib Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2012001133A 2009-10-30 2012-04-30 Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo. CL2012001133A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US25666909P	2009-10-30	2009-10-30
US25669009P	2009-10-30	2009-10-30
US26101409P	2009-11-13	2009-11-13

Publications (1)

Publication Number	Publication Date
CL2012001133A1 true CL2012001133A1 (es)	2013-08-02

Family

ID=43922622

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012001133A CL2012001133A1 (es)	2009-10-30	2012-04-30	Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo.

Country Status (16)

Country	Link
US (2)	US20120316137A1 (es)
EP (2)	EP2493460A4 (es)
JP (1)	JP2013509444A (es)
KR (1)	KR20120115237A (es)
CN (1)	CN102770129A (es)
AU (1)	AU2010313152A1 (es)
CA (1)	CA2777128A1 (es)
CL (1)	CL2012001133A1 (es)
CR (1)	CR20120202A (es)
EA (1)	EA201290255A1 (es)
IL (1)	IL218987A0 (es)
MX (1)	MX2012005023A (es)
NI (1)	NI201200072A (es)
PH (1)	PH12012500809A1 (es)
WO (1)	WO2011053938A1 (es)
ZA (1)	ZA201202256B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1973545T3 (da)	2005-12-23	2013-02-25	Ariad Pharma Inc	Bicykliske heteroarylforbindelser
US20130209543A1 (en) *	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
CN103570724B (zh) *	2012-07-27	2015-12-16	中国科学院广州生物医药与健康研究院	ponatinib 的合成方法
CN110123759A (zh)	2012-12-03	2019-08-16	曼丽国际有限公司	Umirolimus及其衍生物用于治疗癌症的用途
CA2815506C (en)	2012-12-12	2018-12-11	Ariad Pharmaceuticals, Inc.	Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2013204506B2 (en) *	2012-12-13	2016-05-05	Takeda Pharmaceuticals U.S.A., Inc.	Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
KR20150123250A (ko)	2013-03-06	2015-11-03	제넨테크, 인크.	암 약물 내성의 치료 및 예방 방법
US20140343282A1 (en)	2013-05-16	2014-11-20	Apicore, Llc	Processes for making ponatinib and intermediates thereof
EP3016954B1 (en) *	2013-07-04	2018-10-31	Sandoz AG	Crystalline forms of ponatinib hydrochloride
ES2658400T3 (es) *	2013-07-30	2018-03-09	Fresenius Kabi Deutschland Gmbh	Almidón hidroxialquilado para el tratamiento de neoplasias hematológicas
CN104650086A (zh) *	2013-11-22	2015-05-27	天津市汉康医药生物技术有限公司	盐酸帕纳替尼化合物
WO2015085971A1 (en) *	2013-12-09	2015-06-18	Zentiva, K.S.	Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
WO2015085972A1 (en) *	2013-12-09	2015-06-18	Zentiva, K.S.	NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
WO2015085973A1 (en) *	2013-12-09	2015-06-18	Zentiva, K.S.	Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt
WO2015100322A1 (en)	2013-12-24	2015-07-02	Oncotartis, Inc.	Benzamide and nicotinamide compounds and methods of using same
CN104496995A (zh) *	2014-01-06	2015-04-08	广东东阳光药业有限公司	制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
EP3154589A1 (en)	2014-06-13	2017-04-19	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
CN105267200A (zh) *	2014-07-01	2016-01-27	中国科学院上海有机化学研究所	一种黄酮类化合物的应用
WO2016127074A1 (en)	2015-02-06	2016-08-11	Blueprint Medicines Corporation	2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
NZ742351A (en)	2015-11-02	2023-03-31	Blueprint Medicines Corp	Inhibitors of ret
UY37155A (es)	2016-03-17	2017-10-31	Blueprint Medicines Corp	Inhibidores de ret
EP3443001B1 (en)	2016-04-11	2025-04-30	Obsidian Therapeutics, Inc.	REGULATED BIOCIRCUIT SYSTEMS
WO2018017983A1 (en)	2016-07-22	2018-01-25	Blueprint Medicines Corporation	Compounds useful for treating disorders related to ret
CN106236732A (zh) *	2016-08-31	2016-12-21	佛山市弘泰药物研发有限公司	一种依维莫司软胶囊的制备方法
EA201991197A1 (ru) *	2016-12-15	2020-01-13	Ариад Фармасьютикалз, Инк.	БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
CN108047230B (zh) *	2017-12-29	2020-04-17	深圳蓝新科技有限公司	帕纳替尼的制备方法
EP3773589B1 (en)	2018-04-03	2023-11-01	Blueprint Medicines Corporation	Ret inhibitor for use in treating cancer having a ret alteration
CN109875999B (zh) *	2018-05-29	2022-07-12	上海交通大学医学院附属第九人民医院	泊那替尼在kit突变型恶性黑色素瘤中的应用
EP3781568A1 (en)	2018-06-22	2021-02-24	Johnson Matthey Public Limited Company	Form of ponatinib
WO2020113210A1 (en) *	2018-12-01	2020-06-04	The Regents Of The University Of Colorado, A Body Corporate	Functional screen for small molecule and monoclonal antibody drug sensitivity in multiple myeloma patients
EP3861990A4 (en)	2019-12-09	2022-02-23	Ascentage Pharma (Suzhou) Co., Ltd.	PHARMACEUTICAL COMPOSITION OF ALKINYL-CONTAINING COMPOUND, PROCESS FOR PRODUCTION THEREOF AND APPLICATION THEREOF
US20230183810A1 (en) *	2020-05-04	2023-06-15	Dna-Seq, Inc.	Methods and systems for determination of an effective therapeutic regimen and drug discovery
CA3183728A1 (en)	2020-05-29	2021-12-02	Blueprint Medicines Corporation	Solid forms of pralsetinib
WO2022105836A1 (en) *	2020-11-19	2022-05-27	Guangzhou Healthquest Pharma Co., Ltd.	Combination therapies for treating cancer
CN114796227B (zh) *	2022-05-30	2023-12-01	中山大学	Ponatinib在制备预防或治疗血管退行性疾病药物中的应用及该药物

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4316885A (en)	1980-08-25	1982-02-23	Ayerst, Mckenna And Harrison, Inc.	Acyl derivatives of rapamycin
US4650803A (en)	1985-12-06	1987-03-17	University Of Kansas	Prodrugs of rapamycin
US5023264A (en)	1990-07-16	1991-06-11	American Home Products Corporation	Rapamycin oximes
US5023263A (en)	1990-08-09	1991-06-11	American Home Products Corporation	42-oxorapamycin
US5221670A (en)	1990-09-19	1993-06-22	American Home Products Corporation	Rapamycin esters
US5233036A (en)	1990-10-16	1993-08-03	American Home Products Corporation	Rapamycin alkoxyesters
US5120842A (en)	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
US5100883A (en)	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en)	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
US5118677A (en)	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
US5162333A (en)	1991-09-11	1992-11-10	American Home Products Corporation	Aminodiesters of rapamycin
US5177203A (en)	1992-03-05	1993-01-05	American Home Products Corporation	Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5480988A (en)	1992-10-13	1996-01-02	American Home Products Corporation	Carbamates of rapamycin
US5480989A (en)	1992-10-13	1996-01-02	American Home Products Corporation	Carbamates of rapamycin
US5434260A (en)	1992-10-13	1995-07-18	American Home Products Corporation	Carbamates of rapamycin
US5302584A (en)	1992-10-13	1994-04-12	American Home Products Corporation	Carbamates of rapamycin
US5489680A (en)	1992-10-13	1996-02-06	American Home Products Corporation	Carbamates of rapamycin
US5411967A (en)	1992-10-13	1995-05-02	American Home Products Corporation	Carbamates of rapamycin
US5262423A (en)	1992-10-29	1993-11-16	American Home Products Corporation	Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en)	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en)	1992-11-19	1993-11-09	American Home Products Corporation	Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en)	1993-04-23	1996-04-02	American Home Products Corporation	Biotin esters of rapamycin
US5378836A (en)	1993-10-08	1995-01-03	American Home Products Corporation	Rapamycin oximes and hydrazones
US5373014A (en)	1993-10-08	1994-12-13	American Home Products Corporation	Rapamycin oximes
US5391730A (en)	1993-10-08	1995-02-21	American Home Products Corporation	Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385908A (en)	1993-11-22	1995-01-31	American Home Products Corporation	Hindered esters of rapamycin
US5385909A (en)	1993-11-22	1995-01-31	American Home Products Corporation	Heterocyclic esters of rapamycin
US5385910A (en)	1993-11-22	1995-01-31	American Home Products Corporation	Gem-distributed esters of rapamycin
US5389639A (en)	1993-12-29	1995-02-14	American Home Products Company	Amino alkanoic esters of rapamycin
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5463048A (en)	1994-06-14	1995-10-31	American Home Products Corporation	Rapamycin amidino carbamates
US5491231A (en)	1994-11-28	1996-02-13	American Home Products Corporation	Hindered N-oxide esters of rapamycin
US5563145A (en)	1994-12-07	1996-10-08	American Home Products Corporation	Rapamycin 42-oximes and hydroxylamines
US5780462A (en)	1995-12-27	1998-07-14	American Home Products Corporation	Water soluble rapamycin esters
US6258823B1 (en)	1996-07-12	2001-07-10	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en)	1997-09-26	2003-10-11	Abbott Lab	Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
JP2000119181A (ja)	1998-10-06	2000-04-25	Kureha Chem Ind Co Ltd	エスクレチン及びその誘導体の放出制御経口製剤
AU783158B2 (en)	1999-08-24	2005-09-29	Ariad Pharmaceuticals, Inc.	28-epirapalogs
US6277983B1 (en)	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
BR0307544A (pt)	2002-02-01	2004-12-07	Ariad Gene Therapeutics Inc	Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
GB0229022D0 (en) *	2002-12-12	2003-01-15	Novartis Ag	Organic Compounds
EP1648900A4 (en)	2003-07-11	2010-02-10	Ariad Pharma Inc	PHOSPHORUS MACROCYCLES
JPWO2005063720A1 (ja) *	2003-12-25	2007-07-19	日本新薬株式会社	アミド誘導体及び医薬
GB0512324D0 (en) *	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
GB0417905D0 (en) *	2004-08-11	2004-09-15	Novartis Ag	Organic compounds
EP1871377A1 (en)	2005-02-25	2008-01-02	Kudos Pharmaceuticals Ltd	2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
GB0504994D0 (en)	2005-03-11	2005-04-20	Biotica Tech Ltd	Novel compounds
DK1973545T3 (da)	2005-12-23	2013-02-25	Ariad Pharma Inc	Bicykliske heteroarylforbindelser
SI1973545T1 (sl) *	2005-12-23	2013-04-30	Ariad Pharmaceuticals, Inc.	Spojine bicikličnega heteroarila
KR20080083188A (ko)	2006-01-11	2008-09-16	아스트라제네카 아베	모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
BRPI0710496A2 (pt) *	2006-04-07	2011-08-16	Novartis Ag	combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase
WO2007129044A1 (en)	2006-05-03	2007-11-15	Astrazeneca Ab	Thiazole derivatives and their use as anti-tumour agents
US20090306126A1 (en)	2006-05-22	2009-12-10	Astrazeneca Ab	Indole Derivatives
JP2010501537A (ja)	2006-08-24	2010-01-21	アストラゼネカアクチボラグ	増殖性障害の治療に有用なモルホリノピリミジン誘導体
JP5534811B2 (ja)	2006-08-24	2014-07-02	アストラゼネカアクチボラグ	増殖性疾患の治療に有用なモルホリノピリミジン誘導体
WO2008032089A1 (en)	2006-09-14	2008-03-20	Astrazeneca Ab	4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032041A1 (en)	2006-09-14	2008-03-20	Astrazeneca Ab	Pyrimidine derivatives having inhibitory activity against pi3k enzymes
WO2008032091A1 (en)	2006-09-14	2008-03-20	Astrazeneca Ab	4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
JP2010503649A (ja)	2006-09-14	2010-02-04	アストラゼネカアクチボラグ	ピリミジン誘導体
WO2008032033A1 (en)	2006-09-14	2008-03-20	Astrazeneca Ab	4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032077A1 (en)	2006-09-14	2008-03-20	Astrazeneca Ab	Pyrimidine derivatives
WO2008032060A1 (en)	2006-09-14	2008-03-20	Astrazeneca Ab	4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en)	2006-09-14	2008-03-20	Astrazeneca Ab	6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090105270A1 (en) *	2007-02-20	2009-04-23	Buser-Doepner Carolyn A	Kinase inhibition and anticancer therapy
JP2010532756A (ja)	2007-07-06	2010-10-14	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
AU2008273892A1 (en)	2007-07-09	2009-01-15	Astrazeneca Ab	Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
US8138183B2 (en)	2007-07-09	2012-03-20	Astrazeneca Ab	Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
BRPI0814818A2 (pt)	2007-07-09	2019-09-10	Astrazeneca Ab	composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
EP2178866A2 (en)	2007-07-09	2010-04-28	AstraZeneca AB	Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ES2396366T3 (es) *	2007-12-10	2013-02-21	Concert Pharmaceuticals Inc.	Inhibidores heterocíclicos de quinasas
TW201221126A (en) *	2010-09-01	2012-06-01	Arqule Inc	Methods for treatment of non-small cell lung cancer

2010
- 2010-11-01 CA CA2777128A patent/CA2777128A1/en not_active Abandoned
- 2010-11-01 US US13/504,251 patent/US20120316137A1/en not_active Abandoned
- 2010-11-01 EP EP10827625.4A patent/EP2493460A4/en not_active Withdrawn
- 2010-11-01 KR KR1020127014086A patent/KR20120115237A/ko not_active Withdrawn
- 2010-11-01 MX MX2012005023A patent/MX2012005023A/es not_active Application Discontinuation
- 2010-11-01 AU AU2010313152A patent/AU2010313152A1/en not_active Abandoned
- 2010-11-01 WO PCT/US2010/055016 patent/WO2011053938A1/en not_active Ceased
- 2010-11-01 EA EA201290255A patent/EA201290255A1/ru unknown
- 2010-11-01 CN CN2010800491501A patent/CN102770129A/zh active Pending
- 2010-11-01 EP EP13189355.4A patent/EP2762142A1/en not_active Withdrawn
- 2010-11-01 PH PH1/2012/500809A patent/PH12012500809A1/en unknown
- 2010-11-01 JP JP2012537178A patent/JP2013509444A/ja active Pending
2012
- 2012-03-28 ZA ZA2012/02256A patent/ZA201202256B/en unknown
- 2012-04-02 IL IL218987A patent/IL218987A0/en unknown
- 2012-04-25 CR CR20120202A patent/CR20120202A/es unknown
- 2012-04-27 NI NI201200072A patent/NI201200072A/es unknown
- 2012-04-30 CL CL2012001133A patent/CL2012001133A1/es unknown
2013
- 2013-03-13 US US13/802,039 patent/US20130178622A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA201290255A1 (ru)	2013-04-30
IL218987A0 (en)	2012-06-28
PH12012500809A1 (en)	2012-11-26
KR20120115237A (ko)	2012-10-17
ZA201202256B (en)	2012-12-27
US20130178622A1 (en)	2013-07-11
MX2012005023A (es)	2012-06-19
WO2011053938A8 (en)	2011-08-11
EP2762142A1 (en)	2014-08-06
JP2013509444A (ja)	2013-03-14
WO2011053938A1 (en)	2011-05-05
CR20120202A (es)	2012-06-12
NI201200072A (es)	2012-08-20
EP2493460A4 (en)	2013-04-24
AU2010313152A1 (en)	2012-04-19
EP2493460A1 (en)	2012-09-05
US20120316137A1 (en)	2012-12-13
CA2777128A1 (en)	2011-05-05
CN102770129A (zh)	2012-11-07

Publication	Publication Date	Title
WO2011053938A8 (en)	2011-08-11	Methods and compositions for treating cancer
CL2007002930A1 (es)	2008-04-04	Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati
UY32695A (es)	2010-12-31	FORMA DE DOSIFICACIÓN FARMACÉUTICA PARA ADMINISTRACIÓN ORAL DE UN INHIBIDOR DE LA FAMILIA Bcl-2
CL2007001870A1 (es)	2008-06-13	Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
IL177283A (en)	2015-10-29	Pyrazolopyrimidine compounds, their use in the preparation of medicines and pharmaceuticals containing them
IL186303A (en)	2013-07-31	1h - benzamideimzole - 4 carboxyamides converted with quarterly carbon in position 2, the pharmaceutical composition containing it and its use for the preparation of a drug @ for the treatment @ of cancer
WO2009085990A3 (en)	2009-09-03	Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
LTC1781298I2 (lt)	2018-09-25	Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
EA201000702A1 (ru)	2010-12-30	Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
IL202505A (en)	2014-11-30	2-oxo-3-benzyl-benzoxazole-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors, drugs containing them and their uses
CL2014000492A1 (es)	2014-10-03	Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
BRPI0816255A2 (pt)	2015-03-17	Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
IL228017A0 (en)	2013-09-30	Quinazolinone derivatives donated at position 5 as anti-cancer agents
WO2007096151A3 (en)	2007-11-01	Inhibitors of p38-kinase for treatment of pulmonary hypertension
BRPI0806531A2 (pt)	2014-04-22	Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2007003100A1 (es)	2008-04-18	Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
BRPI0720637A2 (pt)	2014-04-15	Composto ou um sal farmaceuticamente aceitável, uma forma estereoisomérica, tautomérica ou polimórfica do mesmo, métodos para o tratamento de um hospedeiro e de tratamento de infecção, composição farmacêutica, e, uso do composto
FI4159217T3 (fi)	2024-08-15	Mek-estäjän ja b-raf-estäjän käsittävä yhdistelmä
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
PH12013502277A1 (en)	2020-10-19	Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
CL2007003265A1 (es)	2008-06-06	Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
EP2143724A4 (en)	2011-09-14	NUCLEOUS FUSED CYBLE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF FOR MEDICAL USES
BRPI0814666A2 (pt)	2017-05-09	composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
CL2007002920A1 (es)	2008-06-06	Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
BRPI1009392A2 (pt)	2016-03-08	"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."